← BridgeBio Pharma, Inc. (BBIO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BridgeBio Pharma, Inc. (BBIO)
Pharmaceutical Preparations · market cap $13.0B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
BridgeBio Pharma (BBIO) is a commercial-stage pharmaceutical company with a market cap of ~$17.7B and 725 employees. Its lead asset, acoramidis, is in Phase 3 for amyloidosis and is generating meaningful revenue ($502M in 2025 vs. $222M in 2024), signaling a commercial launch is underway. The company carries a heavy debt load ($2.36B net debt) against $879.9M in cash (~13.4 months runway), making execution and cash generation critical.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AG10 | Phase 2 | Familial ATTR-CM (ATTRm-CM, or FAC) |
| Acoramidis | Phase 3 | Amyloidosis |
| Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) |
Price & technical context
3-month
-13.3%
6-month
-10.1%
12-month
+28.8%
52-wk range
$52.86–$90.17
vs 50-day MA
-12.7%
vs 200-day MA
-9.1%
Realized vol
46.4%
Max drawdown
-27.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BBIO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.